BIODESIX INC (BDSX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$23.96

From 52W high−23.53%

Volume53641.00

Market cap$246.90M

P/E (TTM)—

P/S (TTM)2.4x

Div yield—

Key dataOct 19, 2026

Open

$23.96

From 52W high

−23.53%

Volume

53641.00

Market cap

$246.90M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−20.2x

P/E (TTM)

—

RSI (14)

38.2

MomentumView details →

1D Return

−1.10%

YTD Return

+249.49%

SummaryUpdated Jun 1, 2026

Biodesix, Inc. (NASDAQ:BDSX) is a data-driven diagnostic solutions company founded in 2005 and headquartered in Boulder, Colorado. Originally incorporated as Elston Technologies, Inc., the company went public in October 2020. Biodesix specializes in blood-based diagnostic tests for lung disease, particularly focusing on lung cancer risk assessment and treatment guidance. The company has evolved from a research-focused organization into a commercial-stage diagnostics company with a growing sales force and expanding test portfolio.

Ask drillr about BIODESIX INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−20.2x

EV/Sales

2.8x

P/S (TTM)

2.4x

P/B (TTM)

27.0x

ProfitabilityView details →

Gross Margin

82.50%

Net Margin

−26.97%

EBITDA Margin

−13.89%

ROE (TTM)

−303.61%

ROA (TTM)

−29.12%

Asset Turnover

1.08x

GrowthView details →

Revenue YoY

+34.46%

EPS YoY

+44.09%

FCF YoY

+34.91%

Revenue CAGR 3Y

+32.31%

EPS CAGR 3Y

+29.46%

EBITDA YoY

+49.07%

MomentumView details →

1D Return

−1.10%

YTD Return

+249.49%

1Y Return

+258.99%

RSI (14)

38.2

vs 50D SMA

−10.84%

vs 200D SMA

+32.40%

Capital & dividendView details →

Debt/Equity

7.85x

Current Ratio

2.85x

Quick Ratio

2.85x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.71

EPS Surprise

21.27%

Beats (12Q)

8/12

Next Q EPS Est

−$0.43

Avg Surprise (4Q)

14.25%

Rev Surprise

3.21%

Financials snapshotView financials →

Revenue (TTM)

102.94M

Net Income (TTM)

−27.76M

Op. CF (TTM)

−19.83M

Next earningsNov 2, 2026 →

Latest newsMore news →

BIODESIX INC announced a partnership with Vanderbilt University and Vanderbilt University Medical Center to accelerate development of a radiomics-based test for lung nodule risk assessment.12h ago

Biodesix announced two complementary approaches to molecular residual disease (MRD) monitoring, a tumor-informed program and a tumor-naïve program, drawing on its bioinformatics and diagnostics test development expertise.26d ago

Similar companies

Biosino Bio-Technology & Science Inc.08247.HK Prenetics Global LimitedPRE Exagen Inc.XGN Yunkang Group Limited02325.HK Myriad Genetics, Inc.MYGN Neuronetics, Inc.STIM Find similar companies →

Latest newsMore news →

BIODESIX INC announced a partnership with Vanderbilt University and Vanderbilt University Medical Center to accelerate development of a radiomics-based test for lung nodule risk assessment.12h ago Biodesix announced two complementary approaches to molecular residual disease (MRD) monitoring, a tumor-informed program and a tumor-naïve program, drawing on its bioinformatics and diagnostics test development expertise.26d ago Biodesix reported second quarter 2026 revenue of $26.9 million, a 34% increase year over year, with an 82% gross margin, and maintained its full-year 2026 revenue guidance of $108-114 million.75d ago